Evidence map›Paper›PMID 29345974›Full record

ReviewAnnual review of clinical psychology2018

Cognitive Effects of Cancer and Cancer Treatments.

Tim A Ahles, James C Root

Registry-linked trialAbstract readReview
In one paragraph

Review in Annual review of clinical psychology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07755839 (CanCOG® - Cognitive Rehabilitation in Cancer), which is not on this map. Cited by 224 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
224citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07755839 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

CanCOG® - Cognitive Rehabilitation in Cancer: A Protocol for a Multicenter Pilot Randomized Controlled Trial With Non-central Nervous System Cancer Survivors

TypeinterventionalSponsorAveiro UniversityRan2026 to 2028Enrolled60ConditionsCancer-related Cognitive Impairment, Cancer-related Cognitive Dysfunction, Cancer-related Cognitive Difficulties, Depression and Anxiety SymptomsArmsCanCOG® - Cogntive Rehabilitation in Cancer
3 · Its place in the literature

Who cites it

224 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

164 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tim A AhlesNeurocognitive Research Lab, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA; email: ahlest@mskcc.org , rootj@mskcc.org.
James C RootNeurocognitive Research Lab, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA; email: ahlest@mskcc.org , rootj@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Training and Career Development CoreU54CA132378 · NCI · CITY COLLEGE OF NEW YORK · PI Tim Alan Ahles, ADRIANA ESPINOSA · 2008 to 2026
$28.9M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADRIANA ESPINOSA, FRANCESCA M GANY · 2008 to 2026
$28.1M
OLDER BREAST CANCER PATIENTS: RISK FOR COGNITIVE DECLINER01CA129769 · NCI · GEORGETOWN UNIVERSITY · PI AHLES, TIM ALAN, MANDELBLATT, JEANNE · 2009 to 2020
$7.3M
Cognition In Older Breast Cancer Survivors: Treatment Exposure, APOE, & SmokingR01CA172119 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AHLES, TIM ALAN, HURRIA, ARTI · 2013 to 2017
$3.5M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA129769NCI NIH HHS R01 CA172119NCI NIH HHS U54 CA132378NCI NIH HHS U54 CA137788
6 · The paper itself

Abstract

As the population of cancer survivors has grown into the millions, there has been increasing emphasis on understanding how the late effects of treatment affect survivors' ability to return to work/school, their capacity to function and live independently, and their overall quality of life. This review focuses on cognitive change associated with cancer and cancer treatments. Research in this area has progressed from a pharmacotoxicology perspective to a view of the cognitive change as a complex interaction of aspects of the treatment, vulnerability factors that increase risk for posttreatment cognitive decline, cancer biology, and the biology of aging. Methodological advances include the development of (a) measurement approaches that assess more fine-grained subcomponents of cognition based on cognitive neuroscience and (b) advanced statistical approaches. Conceptual issues that arise from this multidimensional perspective are described in relation to future directions, understanding of mechanisms, and development of innovative interventions.

Indexed as

AgingCancer SurvivorsCognitive DysfunctionAnimalsHumansNeoplasmsagingbiomarkerscancercancer treatmentchemotherapycognitionendocrine therapygeneticsneuroimagingradiation therapy

Identifiers

PMID29345974
PMCPMC9118140

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.